Andy is an entrepreneur and investor with an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is currently Chairman of Arecor, Congenica, Abcodia, and Babraham Bioscience Technologies Ltd (BBT) at the Babraham Research Campus and is a Director of Ieso Digital Health, Silence Therapeutics plc, Cancer Research Technology (commercial arm of CR-UK), and Sensiia. He is an advisor to several investment funds including Cambridge Innovation Capital and the UCL Technology Fund and was, until recently, a director of Cambridge University Hospitals NHS Foundation Trust.
Andy is a Cambridge Graduate with a PhD in Chemistry and an early career spanning positions with ICI (now AstraZeneca) and PA Technology. He was a founder and executive director of Chiroscience plc until its merger with Celltech in 1999 and since that time he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels. He received a CBE for services to life-science investment in 2015.
Clive Page is a Professor of Pharmacology, King’s College London and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease and he has published over 250 scientific papers.
Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, an AIM listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Non Executive Director of Babraham Bioscience Technologies Ltd, as well as being a Trustee of the Babraham Institute in Cambridge and a Non Executive Director of the Board of Peptinnovate Ltd, PreP Biopharma and EpiEndo. Clive started his early career in the Pharmaceutical Industry at Sandoz Ltd, Basel, Switzerland and regularly consults to both the Pharmaceutical and Biotech Industry.
Clive is a recent former Chairman of the Animal Science Group of the Society of Biology and has contributed widely to the public debate about the use of animals in Research.
He was awarded the Society of Biology President’s Medal in 2012 for an outstanding contribution to the life sciences over the previous year. He is a fellow of the Royal Society of Biology and the British Pharmacological Society.
In 2017, Clive was awarded an OBE for Services to Pharmacology.
Karen studied for a degree in biology and PhD in microbiology. Before joining BBSRC, she worked in commercial research and development with both a small biotechnology company and a large corporate. Karen has extensive experience within BBSRC, and the research councils in a broad range of research and innovation strategy areas. She has held a number of senior roles in what is now the BBSRC Capability and Innovation domain, including leading BBSRC business engagement activities, and establishing a knowledge exchange and commercialisation team. More recently, Karen has also been involved in developing the BBSRC research and innovation campus strategy, working on BBSRC’s bioeconomy strategy, and ensuring these enable bioscience research to deliver benefit and impact for the UK.
As Executive Director, Capability and Innovation at, Karen’s responsibilities include:
Jo is an experienced and successful investment professional with more than 10 years in the private equity industry. A qualified accountant, ACA, by training, she has worked in the corporate finance departments of FTSE 100 and FTSE 250 companies.
She is a Non Executive Director on Octopus AIM VCT plc, Start Codon and Babraham Bioscience Technologies Ltd (BBT), at the Babraham Research Campus. She is also a mentor on the Accelerate Program at the Judge Business School, Cambridge.
Jo has had significant board exposure, having held a number of non-executive posts. Having been a member of the Investment Committee of a leading private equity house, Jo is experienced in investment appraisal. Skilled in the evaluation of businesses, her strengths include identifying value creation opportunities at both a revenue and profit level. She has supported businesses in growth through investment and cost management, with a wealth of experience of developing business plans and working with businesses to secure appropriate financing.
Passionate about growing businesses, Jo has worked closely with entrepreneurs/management teams. She has a wealth of experience of arranging, working with and managing complicated shareholder structures, including a broad range of stakeholder groups. She has a proven track record of working with businesses to drive strategic initiatives and deliver outstanding financial results.
Previous non executive roles include Classic Hospitals Ltd, a group of ten private acute hospitals, IDH, the largest provider of NHS dentistry in the UK, and Verna Care, a manufacturer of infection control products.
She has a chemistry degree from Oxford University.
Jane Osbourn is VP Research and Development for MedImmune in Cambridge. MedImmune was formerly Cambridge Antibody Technology (CAT) and is now the global biologics research and development arm of AstraZeneca. An expert in antibody engineering, she has authored many key publications and patents, and made a significant contribution to the discovery and development of marketed drugs (Humira and Benlysta) and more than 40 clinical candidates. She has worked across many therapy areas, heading CAT’s oncology portfolio before becoming VP of Research for CAT and VP R&D for MedImmune Cambridge in 2008. She also leads a global team, based in Gaithersburg US, focused on the development of biosuperior antibody therapies.
Jane is passionate about the development of the UK biotechnology sector and was elected Chair of the Board of Directors of the BioIndustry Association (the UK biotechnology trade association) in 2015. To help support development of biotech in the Cambridge cluster she is also a Director of Babraham Bioscience Technologies Ltd (BBT) and a Director of Cambridge Enterprise. In addition, she has presented at a number of parliamentary Select Committees and has previously served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel. In 2016 she was recognised in the PharmaVoice 100, and also in Fierce Pharma’s “Fierce Women in Biopharma” – one of 15 women in the global industry noteworthy for their leadership, providing mentorship and helping increase opportunities for women in science.
Derek has brought a wealth of experience to the Babraham Research Campus - over 25 years' in the life-science industry as both a scientist and in business development and corporate development, with first-hand experience of establishing biomedical ventures.
Initially a medicinal chemist with Merck, Derek moved into business and corporate development at Chiroscience, (one of the UK first biotech companies which grew from 17 staff to a FTSE 100 company), successfully negotiating and managing several multi-million pound licensing agreements, (Bristol-Myers Squibb, Purdue Pharma, Mariushi) including being part of the team that licensed the UK’s first biotech product, Chirocaine.
In 2000, he co-founded his first company, BioWisdom, an IT/Drug discovery company. Derek was appointed COO at DanioLabs in 2002, a therapeutics company using zebrafish as a model organism for drug discovery, where he grew the company from 4 to 34 employees and raised around £10 million for VC backed companies, before selling DanioLabs to Vastox, (now Summit Plc), for £15 million in 2007.
He joined Babraham Bioscience Technologies Ltd (BBT) in 2008 as Chief Business Officer with responsibility for the knowledge exchange and commercialisation (KEC) of the Babraham Institute’s intellectual property portfolio. During that time he spun out Crescendo Biologics whose business is focussed around intellectual property from the Babraham Institute.
Derek has been a member of the BBT board since October 2008 and became CEO of BBT in 2010. Following restructuring of the business in 2013, BBT’s primary focus has been on the development and management of the campus, with KEC responsibilities returning to the Babraham Institute.
Derek has a 1st degree in Chemistry, a Master in Information Technology, and an MBA as the first cohort of the Cambridge University Judge Business School MBA programme, and is a Chartered Director. He is a non-executive director at RoCRE (Centre for Research & Enterprise) at Rothamsted Research, and One Nucleus. He also sits on the Cambridge University Enterprise Investment Committee.
Becky is responsible for the finance, HR and health & safety functions of Babraham Bioscience Technologies Ltd (BBT). She first joined BBT in February 2002, as the 2nd full time employee. Having completed CIMA qualification training within BBT, Becky qualified in 2008 and was promoted to Chief Financial Officer in November 2017. Becky sits on the BBT Board.
Prior to joining BBT, Becky worked and studied for an advanced modern apprenticeship and gained the Association of Accounting Technicians qualification, completing the final stages of her apprenticeship at Nexan, a start-up VC backed company, in 2001. This gave her an initial insight into the world of R&D start-up businesses.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557